8-K: Marpai Secures $12 Million in Preferred Stock Financing

Marpai, Inc. has announced the closing of a private placement, raising approximately $12.1 million through the sale of Series A Convertible Preferred Stock to accredited investors.

Summary

• Marpai, Inc. has entered into securities purchase agreements with accredited investors for a private placement.
• The offering involves the sale of 12,100 shares of Series A Preferred Stock at $1,000 per share, totaling approximately $12.1 million in gross proceeds.
• The initial closing is expected around July 31, 2026.
• The Series A Preferred Stock is convertible into Common Stock at a $1.00 conversion price, subject to adjustments and beneficial ownership limitations.
• Automatic conversion into Common Stock will occur upon a qualified public offering or a 60% vote of preferred stockholders.
• Preferred stockholders are entitled to an 8% dividend payable in Common Stock upon liquidity events or conversion.
• Mitchell Family Trust II acted as the lead investor, and Steve Mitchell will serve as a board observer for two years.
• The company has agreed to file a registration statement within 60 days of closing and use commercially reasonable efforts to have it become effective within 90 days.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the capital infusion provides necessary funding for growth and strategic initiatives, though the terms of the preferred stock carry potential dilution risks for common shareholders.

Positives

• Successful private placement raising $12.1 million, strengthening the company's financial position.
• Secured investment from accredited investors, including a lead investor, Mitchell Family Trust II.
• The financing is intended to accelerate Marpai's growth, enhance its technology platform, and advance its mission.
• Board observer rights granted to the lead investor, indicating strategic alignment and potential for enhanced governance oversight.
• Agreement to file a registration statement within 60 days, demonstrating commitment to future liquidity for investors.

Negatives

• The issuance of preferred stock with conversion rights and dividends could dilute existing common stockholders.
• The beneficial ownership limitation on conversion may restrict the ability of some investors to convert their shares fully.
• The company is required to file a registration statement, which involves significant legal and administrative effort and cost.

Risks

• The securities issued have not been registered under the Securities Act and may not be resold without registration or an exemption.
• Potential dilution to existing common stockholders upon conversion of preferred stock.
• The company's ability to execute its strategic vision and scale operations is dependent on the effective use of the raised capital.
• The terms of the preferred stock, including conversion price and dividend rights, could impact future financial performance and shareholder value.
• The company must file a registration statement, which is subject to regulatory review and potential delays.

Future Outlook

The company expects to use the net proceeds from the offering for working capital and general corporate purposes, aiming to accelerate its growth trajectory, strengthen its technology-enabled healthcare services platform, and advance its mission of delivering smarter, more efficient healthcare administration solutions.

Management Comments

• "This $12 million investment ensures we are well capitalized to execute our strategic vision, accelerate our technology roadmap, and scale our operations."
• "Mitchell Companies shares our absolute commitment to transforming healthcare administration, and their financial backing provides both the capital and strategic alignment we need to execute the incredible market opportunities ahead and deliver unmatched value to our clients."
• "We are thrilled to back Marpai as they embark on this exciting next phase of growth. Our team has immense confidence in Damien Lamendola and the entire Marpai leadership group. We believe that Damien possesses the exact combination of visionary leadership, deep industry knowledge, and operational focus required to take the Company to new heights. We believe that Marpai is uniquely positioned to build a highly differentiated, world-class healthcare services platform that creates lasting value for employers and partners alike."

Industry Context

StockSavvy.ai notes that this private placement in the healthcare technology sector, specifically within TPA and PBM services, reflects continued investor interest in companies aiming to improve healthcare administration efficiency and cost-effectiveness through technology. The focus on self-funded employers aligns with a growing trend of companies seeking greater control over their healthcare benefits.

Corporate Governance

Related Party Transactions

• The Mitchell Family Trust II, acting as the lead investor, entered into a Board Observer Agreement with Marpai, Inc. whereby Steve Mitchell will serve as a board observer.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of preferred stock convertible into common stock. Existing common shareholders may see their ownership percentage decrease.
• Investors (Preferred Stockholders): Gain equity in Marpai with specific rights, including conversion into common stock and an 8% dividend payable in common stock.
• Management: Gains capital to execute strategic plans and potentially accelerate growth, but also faces obligations related to the registration statement and investor rights.
• Employees: Potential for company growth and increased opportunities if the capital is used effectively to advance technology and operations.

Next Steps

• Initial closing of the Offering on or about July 31, 2026.
• Filing of a registration statement within 60 calendar days of closing.
• Use of proceeds for working capital and general corporate purposes to accelerate growth and technology roadmap.
• Steve Mitchell to serve as a board observer for two years, subject to continued ownership.

Key Dates

Recommendation

Keywords

Marpai, Series A Preferred Stock, Private Placement, Convertible Preferred Stock, Accredited Investors, Healthcare Technology, TPA, PBM